HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of irradiation in combined treatment of head and neck paragangliomas at the Centre of Oncology in Krakow between 1970-2005.

AbstractAIM OF THE STUDY:
Aim of the study is to evaluate the results of postoperative radiotherapy of paragangliomas, prognostic factors and causes of treatment failure.
MATERIAL AND METHODS:
Forty-four patients (39 females and 5 males) aged 20 to 74 years were treated for paraganglioma between 1970 and 2010 at the Centre of Oncology in Kraków. Patient survival probability was estimated with the Kaplan-Meier method. Log-rank tests and Cox proportional hazard model were used in univariate and multivariate analysis, respectively.
RESULTS:
The most common locations of paragangliomas were the following: the ear, carotid body and internal jugular vein bulb. Forty (91%) out of them were benign and 4 - malignant. All patients underwent surgery followed by adjuvant radiotherapy. The delivered dose ranged from 50 to 72 Gy, the mean dose was 60 Gy. Five-year overall survival was 84%. Five-year relapse-free survival was 84%, either. The multivariate analysis has shown that the dose in an independent prognostic factor for the overall survival. The univariate analysis has shown significantly higher 5-year overall survival in patients who received a dose of 60 Gy or higher - 92% vs. 70% in patients who received a dose lower than 60 Gy.
CONCLUSIONS:
Postoperative radiotherapy with doses higher than 60 Gy in patients with paragangliomas is associated with longer overall survival.
AuthorsMagdalena Pęcak, Elżbieta Pluta, Marcin Hetnał, Renata Wróbel-Radecka, Agnieszka Szadurska, Piotr Brandys, Andrzej Kukiełka, Tomasz Dąbrowski, Tomasz Walasek, Jan Skołyszewski
JournalContemporary oncology (Poznan, Poland) (Contemp Oncol (Pozn)) Vol. 18 Issue 3 Pg. 182-6 ( 2014) ISSN: 1428-2526 [Print] Poland
PMID25520578 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: